logo-loader
viewImmuPharma PLC

Analyst sees 'clear rationale' for ImmuPharma to move forward with Lupuzor

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM) and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.

Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate overall compares well to a number of other pivotal studies and has an excellent safety profile.

Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.

Quick facts: ImmuPharma PLC

Price: 13.98 GBX

AIM:IMM
Market: AIM
Market Cap: £23.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Touchstone Exploration confirms potential of its Cacadura-1...

Headlines from the Proactive UK newsroom. Touchstone Exploration (LON:TXP) has confirmed the early promise of its Cacadura-1 well in Trinidad. Average production was 5,180 barrels of oil equivalent per day at the end of its extended flow test or three times more than Touchstone’s daily output...

1 week, 4 days ago

2 min read